SEC Company Response from ADC Therapeutics SA (ADCT) (CIK 0001771910) (ADCT) — Sep 30, 2019
ADC Therapeutics SA (ADCT) (CIK 0001771910)
Date: Sept. 30, 2019 · CIK: 0001771910 · Accession: 0001140361-19-017558
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233659
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Ms. Tonya K. Aldave ADC Therapeutics SA Registration Statement on Form F-1 Registration No. 333-233659
Re:
Dear Ms. Aldave:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 3:30 p.m. Eastern Time on October 2, 2019 or as soon thereafter as is practicable. By separate letter, the underwriters of the issuance of the securities being registered join in this request for acceleration.
We hereby acknowledge that:
•
should the Securities and Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please do not hesitate to contact Deanna L. Kirkpatrick of Davis Polk & Wardwell LLP at (212) 450-4135 or Yasin Keshvargar of Davis Polk & Wardwell LLP at (212) 450-4839 with any questions or comments with respect to this letter.
[Signature Page Follows]
Sincerely,
ADC Therapeutics SA
Show Raw Text
CORRESP
1
filename1.htm
September 30, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Tonya K. Aldave
Re:
ADC Therapeutics SA
Registration Statement on Form F-1
Registration No. 333-233659
Dear Ms. Aldave:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 3:30
p.m. Eastern Time on October 2, 2019 or as soon thereafter as is practicable. By separate letter, the underwriters of the issuance of the securities being registered join in this request for acceleration.
We hereby acknowledge that:
•
should the Securities and Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the
filing; and
•
the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please do not hesitate to contact Deanna L. Kirkpatrick of Davis Polk & Wardwell LLP at (212) 450-4135 or Yasin Keshvargar of Davis Polk & Wardwell LLP at (212) 450-4839 with any questions or comments with respect to this letter.
[Signature Page Follows]
Sincerely,
ADC Therapeutics SA
By:
/s/ Dominique Graz
Name:
Dominique Graz
Title:
General Counsel